Evidence Based Clinical Analytics Supporting the Genetic Addiction Risk Severity (GARS) Assessment to Early Identify Probands in Preaddiction.

Authors :: Blum K
Bowirrat A
Thanos PK
Hanna C
Khalsa J
Baron D
Elman I
Badgaiyan RD
Dennen C
Braverman ER
Carney P
Lewandrowski KU
Sharafshah A
Gold MS
Source :: EC psychology and psychiatry [EC Psychol Psychiatr] 2024 Dec 26; Vol. 13 (1), pp. 1-3.
Publication Year :: 2024
Abstract: Competing Interests: Conflict of Interest KB holds patents both domestic and foreign related to pro-dopamine regulation complexes and genetic testing for addiction risk. Through his company Synaptamine inc., licensed patents on KB220Z to Victory nutrition international, LLC., There are no other conflicts to report.

Tools